Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company") (NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. If you purchased shares of Horizon during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. On October 19, 2015, the New York Times ran an article entitled "Drug Makers Sidestep Barriers on Pricing." The article claimed that certain drug manufacturers, including Horizon, have begun using specialty pharmacies "to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions." If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com. This press release may constitute Attorney Advertising in some jurisdictions.